Imunon Inc (IMNN) - Total Assets
Based on the latest financial reports, Imunon Inc (IMNN) holds total assets worth $8.02 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Imunon Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Imunon Inc - Total Assets Trend (1996–2025)
This chart illustrates how Imunon Inc's total assets have evolved over time, based on quarterly financial data. Explore IMNN long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Imunon Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Imunon Inc's total assets of $8.02 Million consist of 87.3% current assets and 12.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 71.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how Imunon Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Imunon Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Imunon Inc's current assets represent 87.3% of total assets in 2025, an increase from 7.6% in 1996.
- Cash Position: Cash and equivalents constituted 71.5% of total assets in 2025, up from 2.7% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 1996.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Imunon Inc Competitors by Total Assets
Key competitors of Imunon Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Imunon Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.59 | 0.88 | 11.21 |
| Quick Ratio | 1.59 | 0.88 | 11.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.45 Million | $-704.93K | $54.93 Million |
Imunon Inc - Advanced Valuation Insights
This section examines the relationship between Imunon Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.48 |
| Latest Market Cap to Assets Ratio | 0.64 |
| Asset Growth Rate (YoY) | 26.5% |
| Total Assets | $12.29 Million |
| Market Capitalization | $7.82 Million USD |
Valuation Analysis
Below Book Valuation: The market values Imunon Inc's assets below their book value (0.64x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Imunon Inc's assets grew by 26.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Imunon Inc (1996–2025)
The table below shows the annual total assets of Imunon Inc from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $12.29 Million | +26.45% |
| 2024-12-31 | $9.72 Million | -55.67% |
| 2023-12-31 | $21.92 Million | -50.16% |
| 2022-12-31 | $43.98 Million | -40.61% |
| 2021-12-31 | $74.05 Million | +97.31% |
| 2020-12-31 | $37.53 Million | -1.96% |
| 2019-12-31 | $38.28 Million | -18.31% |
| 2018-12-31 | $46.86 Million | -1.39% |
| 2017-12-31 | $47.51 Million | +54.02% |
| 2016-12-31 | $30.85 Million | -37.08% |
| 2015-12-31 | $49.03 Million | -26.49% |
| 2014-12-31 | $66.69 Million | +46.03% |
| 2013-12-31 | $45.67 Million | +80.10% |
| 2012-12-31 | $25.36 Million | -22.33% |
| 2011-12-31 | $32.65 Million | +1192.92% |
| 2010-12-31 | $2.53 Million | -82.94% |
| 2009-12-31 | $14.81 Million | -37.50% |
| 2008-12-31 | $23.69 Million | -39.32% |
| 2007-12-31 | $39.04 Million | +106.23% |
| 2006-12-31 | $18.93 Million | +18.98% |
| 2005-12-31 | $15.91 Million | -6.70% |
| 2004-12-31 | $17.05 Million | +18.09% |
| 2003-12-31 | $14.44 Million | +530.16% |
| 2002-12-31 | $2.29 Million | -22.50% |
| 2001-12-31 | $2.96 Million | -67.57% |
| 2000-12-31 | $9.12 Million | +469.86% |
| 1999-12-31 | $1.60 Million | +383.77% |
| 1998-12-31 | $330.74K | -59.82% |
| 1997-12-31 | $823.21K | -91.17% |
| 1996-12-31 | $9.32 Million | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase fo… Read more